Axa S.A. Theravance Biopharma, Inc. Transaction History

Axa S.A.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$9.65 - $11.34 $1.35 Million - $1.58 Million	-139,725 Reduced 91.07%	13,700 $153,000
Q2 2022 Feb 14, 2023	SELL	$8.41 - $10.34 $278,160 - $341,995	-33,075 Reduced 17.73%	153,425 $1.39 Million
Q2 2022 Aug 15, 2022	SELL	$8.41 - $10.34 $278,160 - $341,995	-33,075 Reduced 17.73%	153,425 $1.39 Million
Q1 2022 Feb 14, 2023	BUY	$8.33 - $12.96 $275,514 - $428,652	33,075 Added 21.56%	186,500 $1.78 Million
Q1 2022 May 13, 2022	SELL	$8.33 - $12.96 $35,819 - $55,728	-4,300 Reduced 2.25%	186,500 $1.78 Million
Q4 2021 Feb 14, 2022	SELL	$7.42 - $11.05 $207,760 - $309,400	-28,000 Reduced 12.8%	190,800 $2.11 Million
Q3 2021 Nov 15, 2021	BUY	$6.77 - $14.41 $1.48 Million - $3.15 Million	218,800 New	218,800 $1.62 Million

122

47.3M

200

12.8K

Ticker TBPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,782,400
Market Cap $618M
Description
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

Stay updated on Axa S.A. with notifications on news.